版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
LohmannAnimalHealthInternationalGainesville,Georgia,USA
Education73-84’BSCal.PolyPomonaMSPoultrySc,AuburnDVM,U.C.DavisBoardcertified92’KenTakeshitaFosterFarms,CAMgr.HealthServices85-90’ArborAcres,CTDir.PoultryHealth,91-95’HealthofUSAPed.,GGP,GPTechnicalSupportUSAVinelandLabsDirectorTech.Service;95-01’Worldwide
KenTakeshitaHomeofficeVacaville,CAbetweenSac/SFMgr.TechnicalServicesWorldwidesupportConcentratedeffortinAmerica’sLohmannAnimalHealthInternationalLAHIformedinOctober2000MergerofVineland-MBL-LohmannHeadquarters=GainesvilleGALohmannAnimalHealthInternationalEffectiveMay1,2001TechnicalSupportTeamDr.KenTakeshita(USA)Dr.EricLovell(USA)[Consultant]Dr.DavidShapiro(USA)[Consultant]Dr.GregCutler(USA)[Consultant]Dr.CharlesHofacre(USA)[Consultant]Open(USA)Open(LatinAmerica)Dr.HeikeScharr(Germany)Dr.vanDijk(Germany)Dr.CherYew(Singapore)Dr.BeatrizCardoso(Brazil)Dr.KarenBurns(USA),1/1/02Internationaltrips~same;4/yrwhereverneededworldwideLessintensedomestictravelMorefocusoncustomerfollowuppresentations/techbulletinstrialsandotherprojects
InactivatedIBDVaccinesBursalTissueOrigin(BTO)ChickEmbryoOriginCells(CEO)TissueCultureOrigin(TCO)IBDvirusbursaTC(TissueCulture)CEO(ChickEmbryoOrigin)BTO/BD(BursalTissueOrigin)/(BursalDerived)-ChickenEmbryoFibroblast(CEF)-PerpetualcelllinesSignificantvirusadaptationrequired-Infected,wholechickembryosharvestedSomevirusadaptationrequired-SPFchickensinfectedbursasharvestedVirusadaptationnotrequiredGrowingtheIBDvirusBursalTissueOrigin(BTO)orBursalDerived(BD)BTOvaccinesstartedinUK
Early1970’sOriginatedbygroupofUKveterinariansWerenothappywithliveIBDvaccinesaloneProbablychoseBTObecause:EasytogrowGrewtohightiterUKgovernmentrequiredstrictpotencytestsChallengeofchicksfromvaccinatedparentsTheirworkshowedverystrongprotectioninchicksfromvaccinatedparents(to4weeks)VaccineworkwasledbyDr.BoxandproducedbyGlaxoBTOshowedasbettervaccineLongerdurationofimmunitywhencomparedtoTCOandCEOvaccinesInUSA,betterabletoprotectagainstvariantIBDstrainsFlock’sVaccinatedwithBursalDerivedIBD~BetterTitersFlock’sVaccinatedwithBursalDerivedIBD~BetterProtectionBTOshowedasbettervaccineProduction:BecauseNOvirusadaptationisrequired,finaloutput“matches”seeds/”matches”challengeViralgrowthVeryhightitersbecausevirusis“home”PotentiallyotherimmunefactorsproducedSocalled“bursin”IncompleteviralparticlesViruscontentwhichis“hidden”fromnormalassaybursaTC(TissueCulture)CEO(ChickEmbryoOrigin)BTO/BD(BursalTissueOrigin)/(BursalDerived)AdaptationofIBDvirusFieldVirusSignificantvirusadaptationrequiredSomevirusadaptationrequiredNovirusadaptationrequiredBTObecamewidelyusedFirstusedinbreedersasonlyIBDvaccineand/oraspartofprogramwithliveprogenyvaccination1stBTOvaccineswere>2xcostofTCorCEOvaccinesAstimemovedfrom1970’sto1980’sUK&EuropebegantodeclineusageRegulatoryissuesFearofCAVinthevaccinesAnimalwelfare(usingchickenstomakevaccine)InterferencewithlivevaccinesUSAmovedsolidlytoBTOIBDvaccinesUsedaloneand/orwithliveprogenyvaccinationExcellentcoverageofvariantstrainsVaccinecompaniesclaiming“100%BTO”MBL®Vineland
®BursalTissueOrigin(BTO)VinelandKilled4way“new”
1823~novariantIBD~reducecostequalorbettertiters/protection~sameNDV,IBV&Reoprotection“New”LAHI-VinelandKilled4way“1823”BursalDerivedHowdoes“new”1823comparewithotherkilled4wayvaccinesforIBD?*ProVacACLisproducedinacontinuous,aviancellline–tumortransformedquailcellline.**OnlyMBLBTO2andMerialcontain100%BTOIBDantigen.IBDtitercomparisonof
“new”1823*vsother4ways*Prelicensingserial**Birdsprimedwithlivevaccination.Titersmeasured4weekspostvaccinationBursalDerived~bettertitersBursalDerived~BetterProtection…evenwithsmalldoseQuickQuestions…....orontoVi-BursaCEVi-BursaCEVi-BursaCEa“classic”IBDvirusintermediate<->intermediate+invasiveness“non”cloned~broadspectrumprobagatedinChickEmbryo~broadspectrumgoodsafetyingoodprotectioninbroilersandlayersgoodprimerforkilledvaccinationVi-BursaCEisa“Classic”IBDvirusViBursaGclassicIBDintermediate=D78tissuecultureViBursaCEclassicIBD
intermed.=BursineIIchickembryoViBursaLclassic/variantIBDisamildwon’theatupIBDvirusTC(TissueCulture)CEO(ChickEmbryoOrigin)BursineIIVi-BursaCED78Vi-BursaGVi-BursaCEisproducedinCEOVi-BursaCE….multipliedinlymphoidtissuex1Vi-BursaCEx2a2a178Clone“Non”-clonedclonedD78“Non”-clonedVi-BursaLVi-BursaCEis“non”cloned“non”clonedVi-BursaCE….doesn’tloseit’santigenicdiversity78787878a2a1a1a2x1x1x2x278a1x2Vi-BursaCE….issafeVi-BursaCE…goodprotectioninSPFbirdsVi-BursaCE…. GoodprotectioninbroilersVi-BursaCE…. GoodprimingofkilledVi-BursaCE….goodfieldresultsRecentDevelopments
Vi-BursaCEOriginalVi-BursaCEOriginalVi-BursaCE~lessinvasivethanintendedRecentworkonVi-BursaCERe-workedVi-BursaCE~moreinvasivethanoldNewVi-BursaCENewVi-BursaCE~intermediate<->intermediate+Summary;
Vi-BursaCEa“classic”IBDvirus“non”cloned~broadspectrumprobagatedinChickEmbryo~broadspectrumintermediate<->intermediate+invasivenessgoodsafetyingoodprotectioninbroilersandlayersgoodprimerforkilledvaccinationSummaryRecentdevelopments
Vi-BursaCE“originally”wasVineland’smostinvasiveIBDbutbecame“mild”“current”serialsaremoreinvasivethanoldserialsprobablyslightlylowerin“invasive”nessthanBursine+….analternativetoBursine/Bursine+?ViBursaGclassicIBDintermediate=D78tissuecultureViBursaCEclassicIBD
strongerintermed.
likeBursineIIchickembryoViBursaLMildcausesminimalimunosuppressionToBreakThruLAHI-VinelandLiveIBDVaccinesSummaryRecentdevelopments
Vi-BursaCE“originally”wasVineland’smostinvasiveIBDbutbecame“mild”“current”serialsaremoreinvasivethanoldserialsprobablyslightlylowerin“invasive”nessthanBursine+….analternativetoBursine/Bursine+?Vaccination/challengetrialinprogresstodetermineprotectionagainstvariantvsBursineIIconfirminvasivenessofnewserials“WordofCaution”Thinkcarefullybeforesharing“Recentdevelopments”Vi-BursaCEwithendusercanbeanadvantagewithnewcustomeracustomerwhodidnotseeanadvantageusingthe“old”serialsofVi-BursaCEcanbeadisadvantagewithacurrentuserofVi-BursaCE
…..decideaheadoftimeQuickQuestions…....orontoPD50LAHI-Vineland’sNDVPD50PD50PD50orViNuChickVac-KspecificallydevelopedforbabychickvaccinationcalledPD50becauseeachdosecontains50protectivedosebychallengetestisa“High”-potencykilledNDV
large#ofprotectioninsmallvolume/dosepotencyby
WeybridgeProtectiveDoseTestPD50“High”potency=0.1mldose50PD50“High”potency10PD500.5mldose“Average”potencyvs.
birdsvaccinatedwithdecreasingpartialdoseP(rotective)D(ose)50(%)isdosewhichprotects50%ofbirdschallengedwith“Hot”NDVvirusPD50WeybridgeProtectiveDoseTest=0.1and0.05ml100%protection0.025ml92%protection0.0125ml70%protection0.00612ml30%protecciónThisisthePD50pointExtrapolating,onePD50unitofthisvaccineis.0.009mlCalculationofPD50perdose;-Ifdoseis0.1ml~potencyofvaccineinPD50units=0.1ml/0.009=11-theabovevaccineundertesthasapotencyof11PD50perdose.ExampleofdeterminingPD50ofavaccinePD500.1mldose>50PD50PD5022-25PD500.5mldose“Average”potencyvs.
“Average”killedNDVusedinlayersis
=22-25xPD50in0.3-0.5ml
“High”potencyLAHI-Vineland’sPD50forchicksis>50xPD50in0.1mlPD50Purpose;preventhighlyvelogenicNDVmortalityMethod;Simultaneouslive&killedNDV@1day
liveNDVtostimulatesshortlived(3-5weeks)“local”(IgA)respiratorymucosalliningimmunityhighpotencykilledtostimulateslonglasting“systemic”(IgG)immunity(@least7-8weeks)
note;it’sessentialthatkilledNDV=“High”PotencyPD50Goalof“Simultaneous”live&killedNDVisfor;MiddleEast;reducemortality40%to4%Mexico;simultaneouskilled/liveeffectiveB1live+LAHI-Vineland’sPD50@1dayLaSota@7-10days+/-LaSota@18dayinhighchallengePD50FieldExperiencePD50FieldExperience;SerologyNosignificantantibodytiterafterdayoldkilledOnlyhightitersafterchallengehightiter+mortality/clinicalsigns~poorprotectionhightiter+nomortality/clinicalsigns~goodprotectionlowtiters~nochallengePD50FieldExperience;SerologyPD50FieldExperience;SerologyThailand
@least0.1ml@1dayofage…challengedependent500mlbottle=5,000dosagesinjectIMinlegorSQinneckPD50Recommendations&Usagewait6hrsbetweenMarek’s&LAHI-Vineland’sPD50preferably
vaccinateindifferentsitefromMarek’sCautionLAHI-Vineland’sNDVQuestions?PD50Questions/AnswersQ.Whatisdifferencebetween“highpotency”PD50vsaveragekilledNDVvsStandardKilledNewcastlevaccines.A.TheantigenamountcontainedinPD50isconsiderablyhigherthanthatinakilledNDVusedinolderlayers.TheprotectiongiventothechickensisconsiderablysuperiorusingViNuChickVacKPD50.PD50Questions/AnswersQ.WhyaretheredifferentkilledNDVrecommendedforbroilerchickensandanotheronerecommendedforlayers?
A.1)Smallerdose,0.1vs0.5ml,ispreferredforonedayoldbroilersbecauseofsizeofbirds2)Higherpotencyispreferredfordayoldbroilersvslayersbecauseofhigherearlierchallenge….particularlywherevelogenicNDVispresent.PD50Questions/Ans
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 外科用肩绷带相关项目建议书
- 基因组信息分析仪项目评价分析报告
- 含药物的口腔护理制剂项目评价分析报告
- 做自己的中医
- 宝鸡文理学院《材料力学性能》2022-2023学年第一学期期末试卷
- 数字打字用铅字项目评价分析报告
- 无碳纸相关项目实施方案
- 有线电视接收器项目评价分析报告
- 部编版三年级语文上册第六单元《这儿真美》教学课件
- 印刷版项目可行性实施报告
- 2024年新人教版七年级上册数学课件 3.1 第3课时 反比例关系
- 中华民族现代文明有哪些鲜明特质?建设中华民族现代文明的路径是什么?参考答案
- 教育家精神引领高校教师成长的解释框架、认知坐标与行动路径
- 高职市场营销专业《市场调查与预测》说课稿
- Unit3 My Weekend Plan(教学设计)-2024-2025学年人教PEP版英语六年级上册
- 流产补偿协议样书
- 2024年秋季1530安全教育记录
- DL-T5704-2014火力发电厂热力设备及管道保温防腐施工质量验收规程
- 中外政治思想史-形成性测试四-国开(HB)-参考资料
- 扑克牌搭高塔 课件(16张PPT) 小学班会活动
- 龙井茶PPT课件.ppt
评论
0/150
提交评论